Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Hydroxychloroquine and Azithromycin for COVID-19 (AMBUCOV)
NCT04954040Phase 2Unknown
- Sponsor
- Maimónides Institute of Biomedical Research of Córdoba
- Start
- Feb 2021
- Primary completion
- Oct 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial in coronavirus disease 2019 (COVID-19) and acute respiratory distress syndrome (ARDS) comparing Hydroxychloroquine + Azithromycin with SOC (Standard of Care) (2 arms). Primary endpoints: Hospitalization at 28 days, ICU admission at 28 days and 1 more. Status: unknown.
02
Drugs
hydroxychloroquineazithromycin
03
Conditions
coronavirus disease 2019 (COVID-19)acute respiratory distress syndrome (ARDS)
Beyond the preview
Go deeper on NCT04954040.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04954040.